A phenotypic screen for compounds that reverse cAMP-mediated suppression of T cell functions
Open Access
- 3 April 2022
- journal article
- research article
- Published by Elsevier in SLAS Discovery
- Vol. 27 (5) , 314-322
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AI121069, P30CA118100, UL1TR001449)
- University of Connecticut
This publication has 27 references indexed in Scilit:
- Flow Cytometry: Impact on Early Drug DiscoverySLAS Discovery, 2015
- A High-Throughput Phenotypic Screen of Cytotoxic T Lymphocyte Lytic Granule Exocytosis Reveals Candidate ImmunosuppressantsSLAS Discovery, 2015
- Immunity, inflammation and cancer: a leading role for adenosineNature Reviews Cancer, 2013
- Modulation of T cell immune functions by the prostaglandin E2 – cAMP pathway in chronic inflammatory statesBritish Journal of Pharmacology, 2012
- T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cellsJournal of Immunological Methods, 2010
- Combined Spatial and Enzymatic Regulation of Csk by cAMP and Protein Kinase A Inhibits T Cell Receptor SignalingJournal of Biological Chemistry, 2003
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Proliferation of Mouse Primordial Germ Cells in Vitro: A Key Role for cAMPDevelopmental Biology, 1993
- Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanismsIn Vitro Cellular & Developmental Biology - Animal, 1992
- Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cellsEuropean Journal of Immunology, 1988